Biotechnology major BioCon is likely to take its group entity Biocon Biologics public and is expected to raise about $500M. Source: BioSpace

With a priority review voucher in hand, Teva is expecting the FDA to rule on its new migraine treatment fremanezumab by June. Source: BioSpace

Arno Therapeutics is calling it quits. It sold off all its assets, with the final asset being the rights to Onapristone, which it sold to Context Biopharma. Source: BioSpace

Immuno-oncology therapeutics have revolutionized certain types of cancer treatments, and they are, in many ways, as close to miracle cures as we’ve seen in decades. Source: BioSpace

Next year should be enormously important for Canadian marijuana stocks, as the country moves forward with legalization of recreational marijuana. Source: BioSpace

Shares of Agile plunged more than 62 percent in early trading after the company announced this morning the FDA rejected its low-dose hormonal contraceptive patch called Twirla. Source: BioSpace

Five Prime and Zai Lab today announced an exclusive license agreement for FPA144 in Greater China and global strategic development collaboration. Source: BioSpace

Forbes recently interviewed Nazli Azimi, the CEO and co-founder of Bioniz Therapeutics. Source: BioSpace

The total capital raised by Flagship to fuel its institutional innovation and venture creation platform now exceeds $2.3B. Source: BioSpace

Arpita Dutt, writing for Zacks, predicts what the three hot areas for approvals are likely to be in 2018. Source: BioSpace